# Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer

> **NCT01202890** · PHASE1 · TERMINATED · sponsor: **New Mexico Cancer Research Alliance** · enrollment: 1 (actual)

## Conditions studied

- Ovarian Cancer
- Epithelial Ovarian Cancer
- Fallopian Tube Carcinoma
- Primary Peritoneal Carcinoma

## Interventions

- **DRUG:** Lenalidomide, Liposomal Doxorubicin, Bevacizumab
- **DRUG:** Revlimid, Doxil, Avastin

## Key facts

- **NCT ID:** NCT01202890
- **Lead sponsor:** New Mexico Cancer Research Alliance
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-09
- **Primary completion:** 2011-05
- **Final completion:** 2012-05
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Terminated due to inadequate rate of accrual.
- **Last updated:** 2014-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01202890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01202890, "Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01202890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*